ArticleInternational journal of nanomedicine2021
Potentiality of Melittin-Loaded Niosomal Vesicles Against Vancomycin-Intermediate
Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Mechanistic evaluation of niosomal Rhoifolin in antileishmanial therapy and its additive potential with meglumine antimoniate.Scientific reports · 2026Article
- Preparation and Characterization of Niosomes Containing Cationic Antimicrobial Peptides WSKK11 and WSRR11.ACS omega · 2026Article
- Enhanced Antimicrobial Activity of Ciprofloxacin Encapsulated in Sophorolipid-Based Nano-Assemblies Against Ciprofloxacin-/Methicillin-ResistantPharmaceutics · 2026Article
- Progress in topical nanoformulations against bacterial skin and soft tissue infections- current trends.Drug delivery and translational research · 2025Review
- Multifunctional nano-delivery system based on DNase I and photodynamic therapy for combatting enterococcus faecalis biofilm infections.Scientific reports · 2025Article
- Gramicidin and chlorhexidine encapsulated in bicontinuous microemulsions: antimicrobial activity performance and their impact on self-assembly.Journal of surfactants and detergents · 2025Article
- Exploring intracellular anti-mycobacterium activity of lactoferricin-loaded niosomes: proteomics insights into Immunomodulation.Scientific reports · 2025Article
- Emerging Antimicrobial Strategies Against Heterogeneous and Vancomycin-IntermediateInternational journal of general medicine · 2025Review
- Multifunctional poloxamer-based thermo-responsive hydrogel loaded with human lactoferricin niosomes:International journal of pharmaceutics: X · 2024Article
- Anticancer potentiality of Hottentotta saulcyi scorpion curd venom against breast cancer: an in vitro and in vivo study.Scientific reports · 2024Article
- Staphylococcus aureus and biofilms: transmission, threats, and promising strategies in animal husbandry.Journal of animal science and biotechnology · 2024Review
- Customizable Microfluidic Devices: Progress, Constraints, and Future Advances.Current drug delivery · 2024Review
- The impact of solvent selection on the characteristics of niosome nanoparticles prepared by microfluidic mixing.International journal of pharmaceutics: X · 2023Article
- New Weapons to Fight againstAntibiotics (Basel, Switzerland) · 2023Review
- Ethanolic Extract Propolis-Loaded Niosomes Diminish Phospholipase B1, Biofilm Formation, and Intracellular Replication ofMolecules (Basel, Switzerland) · 2023Article
- Nano-Delivery System of Ethanolic Extract of Propolis TargetingNanomaterials (Basel, Switzerland) · 2023Article
- Niosome as an Effective Nanoscale Solution for the Treatment of Microbial Infections.BioMed research international · 2023Review
- Monkeypox virus: An emerging epidemic.Microbial pathogenesis · 2022Review
- Characterisation of niosome nanoparticles prepared by microfluidic mixing for drug delivery.International journal of pharmaceutics: X · 2022Article
- Monkeypox: Emerging virus of concern; antivirals and vaccines therapeutic options.Microbial pathogenesis · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsThe antibacterial activity of melittin (Mel) on
resultsThe effective inhibitory activity of Mel on skin pathogens was demonstrated. Among the tested strains, VISA was most susceptible to Mel. Regarding to its function, Mel targeted the bacterial cell envelope and disrupted cell membrane integrity. Mel-loaded NISVs were successfully fabricated with a nano-size of 120-200 nm and entrapment efficiency of greater than 90%. Moreover, Mel-loaded NISVs were taken up and accumulated in the intracellular space. Meanwhile, Mel was released and distributed throughout the cytosol and nucleus. Mel-loaded NISVs efficiently inhibited the growth of bacteria, particularly MRSA and VISA. Importantly, they not only penetrated epidermal and dermal skin layers, but also reduced the bacterial growth in infected skin.
conclusionMel-loaded NISVs have a great potential to exhibit antibacterial activity. Therapeutic application of Mel-loaded NISVs could be further developed as an alternative platform for the treatment of skin infection via dermal and transdermal delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.